| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article
- Language: English
- [Parasite Immunol] 2024 May; Vol. 46 (5), pp. e13038.
- MeSH Terms: Toxoplasmosis, Ocular* / genetics ; Toxoplasmosis, Ocular* / immunology ; Toxoplasmosis, Ocular* / parasitology ; Interleukin-17* / genetics ; Humans ; Male ; Female ; Adult ; Brazil ; Middle Aged ; Young Adult ; Polymorphism, Single Nucleotide ; Genetic Predisposition to Disease ; Polymorphism, Restriction Fragment Length ; Protective Factors ; Adolescent ; Genotype ; Polymorphism, Genetic ; Polymerase Chain Reaction ; Aged
- References: M. Maenz, D. Schlüter, O. Liesenfeld, G. Schares, U. Gross, and U. Pleyer, “Ocular Toxoplasmosis Past, Present and New Aspects of an Old Disease,” Progress in Retinal and Eye Research 39 (March 2014): 77–106, https://doi.org/10.1016/j.preteyeres.2013.12.005. ; V. Greigert, F. Bittich‐Fahmi, and A. W. Pfaff, “Pathophysiology of Ocular Toxoplasmosis: Facts and Open Questions,” PLoS Neglected Tropical Diseases 14, no. 12 (December 2020): e0008905, https://doi.org/10.1371/journal.pntd.0008905. ; J. Garweg, “Ocular Toxoplasmosis: An Update,” Klinische Monatsblätter für Augenheilkunde 233, no. 4 (April 2016): 534–539, https://doi.org/10.1055/s‐0041‐111821. ; T. S. de Santana, M. G. B. Meirelles, M. P. Ávila, et al., “Toxoplasmosis Retinochoroiditis Resistant to Sulfa Treatment,” Brazilian Journal of Development 7, no. 3 (2021): 25454–25463, https://doi.org/10.34117/bjdv7n3‐311. ; U. Pleyer, D. Schlüter, and M. Mänz, “Ocular Toxoplasmosis: Recent Aspects of Pathophysiology and Clinical Implications,” Ophthalmic Research 52, no. 3 (2014): 116–123, https://doi.org/10.1159/000363141. ; M. G. Netea, J. Domínguez‐Andrés, L. B. Barreiro, et al., “Defining Trained Immunity and Its Role in Health and Disease,” Nature Reviews. Immunology 20, no. 6 (March 2020): 375–388, https://doi.org/10.1038/s41577‐020‐0285‐6. ; M. Normanton and L. C. Marti, “Current Data on IL‐17 and Th17 Cells and Implications for Graft Versus Host Disease,” einstein (Sao Paulo) 11, no. 2 (June 2013): 237–246, https://doi.org/10.1590/s1679‐45082013000200019. ; A. Sauer, A. W. Pfaff, O. Villard, et al., “Interleukin 17A as an Effective Target for Anti‐Inflammatory and Antiparasitic Treatment of Toxoplasmic Uveitis,” The Journal of Infectious Diseases 206, no. 8 (August 2012): 1319–1329, https://doi.org/10.1093/infdis/jis486. ; A. de‐la‐Torre, A. Sauer, A. W. Pfaff, et al., “Severe South American Ocular Toxoplasmosis Is Associated With Decreased Ifn‐γ/Il‐17a and Increased Il‐6/Il‐13 Intraocular Levels,” PLoS Neglected Tropical Diseases 7, no. 11 (November 2013): e2541, https://doi.org/10.1371/journal.pntd.0002541. ; S. L. Gaffen, “Structure and Signalling in the IL‐17 Receptor Family,” Nature Reviews. Immunology 9, no. 8 (July 2009): 556–567, https://doi.org/10.1038/nri2586. ; S. Vidal, L. Puig, J.‐M. Carrascosa‐Carrillo, Á. González‐Cantero, J.‐C. Ruiz‐Carrascosa, and A.‐M. Velasco‐Pastor, “From Messengers to Receptors in Psoriasis: The Role of IL‐17RA in Disease and Treatment,” International Journal of Molecular Sciences 22, no. 13 (June 2021): 6740, https://doi.org/10.3390/ijms22136740. ; J. L. Espinoza, A. Takami, K. Nakata, et al., “A Genetic Variant in the IL‐17 Promoter Is Functionally Associated With Acute Graft‐Versus‐Host Disease After Unrelated Bone Marrow Transplantation,” PLoS One 6, no. 10 (October 2011): e26229, https://doi.org/10.1371/journal.pone.0026229. ; M. Kawaguchi, D. Takahashi, N. Hizawa, et al., “IL‐17F Sequence Variant (His161Arg) Is Associated With Protection Against Asthma and Antagonizes Wild‐Type IL‐17F Activity,” The Journal of Allergy and Clinical Immunology 117, no. 4 (April 2006): 795–801, https://doi.org/10.1016/j.jaci.2005.12.1346. ; J. R. Vidal‐Castiñeira, A. López‐Vázquez, R. Diaz‐Peña, et al., “A Single Nucleotide Polymorphism in the Il17ra Promoter Is Associated With Functional Severity of Ankylosing Spondylitis,” PLoS One 11, no. 7 (July 2016): e0158905, https://doi.org/10.1371/journal.pone.0158905. ; Y.‐G. Kim, E.‐Y. Kim, C.‐G. Ihm, et al., “Gene Polymorphisms of Interleukin‐17 and Interleukin‐17 Receptor Are Associated With End‐Stage Kidney Disease,” American Journal of Nephrology 36, no. 5 (2012): 472–477, https://doi.org/10.1159/000343571. ; J. Dormans, S. Grant, N. Rendon, et al., “A Genome Wide Association Study Identifies an IL17RC Missense Mutation (S111 L) as an Adolescent Idiopathic Scoliosis Locus.” Paper presented at the 60th American Society of Human. Genetics Meeting 2010, Washington, DC. Platform Session 51: Polygenic Traits: GWAS Methods and Results, November 2010; p. 99. ; G. Vargas‐Alarcón, J. Angeles‐Martínez, T. Villarreal‐Molina, et al., “Interleukin‐17A Gene Haplotypes Are Associated With Risk of Premature Coronary Artery Disease in Mexican Patients From the Genetics of Atherosclerotic Disease (GEA) Study,” PLoS One 10, no. 1 (January 2015): e0114943, https://doi.org/10.1371/journal.pone.0114943. ; M. A. Rocha Loures, L. C. Macedo, D. M. Reis, et al., “Influence of TNF and IL17 Gene Polymorphisms on the Spondyloarthritis Immunopathogenesis, Regardless of HLA‐B27, in a Brazilian Population,” Mediators of Inflammation 2018 (2018): 1–7, https://doi.org/10.1155/2018/1395823. ; S. Gao, C. Mao, J. Cheng, Q. Deng, and W. Sheng, “Association of IL‐17A‐197G/A and IL‐17F‐7488T/C Polymorphisms and Osteoarthritis Susceptibility: A Meta‐Analysis,” International Journal of Rheumatic Diseases 23, no. 1 (October 2019): 37–46, https://doi.org/10.1111/1756‐185x.13737. ; A. Batalla, E. Coto, J. Gómez, et al., “IL17RA Gene Variants and Anti‐TNF Response Among Psoriasis Patients,” The Pharmacogenomics Journal 18, no. 1 (January 2018): 76–80, https://doi.org/10.1038/tpj.2016.70. ; D. Sabry, N. Aboraia, and M. Samir, “A Potential Association Between Psoriasin to rs4819554 of IL‐17RA Gene Polymorphism in Psoriasis Egyptian Patients,” Archives of Dermatological Research 312, no. 4 (November 2020): 273–281, https://doi.org/10.1007/s00403‐019‐02011‐x. ; M. Hristova, Z. Kamenarska, G. Dzhebir, et al., “The Role of IL‐17 rs2275913, IL‐17RC rs708567 and TGFB1 rs1800469 SNPs and IL‐17A Serum Levels in Patients With Lupus Nephritis,” Rheumatology International 41, no. 12 (September 2021): 2205–2213, https://doi.org/10.1007/s00296‐021‐04996‐z. ; M. S. Dutra, S. R. Bela, A. L. Peixoto‐Rangel, et al., “Association of a NOD2 Gene Polymorphism and T‐Helper 17 Cells With Presumed Ocular Toxoplasmosis,” The Journal of Infectious Diseases 207, no. 1 (October 2012): 152–163, https://doi.org/10.1093/infdis/jis640. ; “Photocoagulation for Diabetic Macular Edema. Early Treatment Diabetic Retinopathy Study Report Number 1. Early Treatment Diabetic Retinopathy Study Research Group,” Archives of Ophthalmology 103 (1985): 1796–1806, https://doi.org/10.1001/archopht.1985.01050120030015. ; I. B. Gomes, C. M. Ayo, A. G. Lopes, et al., “Influence of Interleukin 17 A and 17 F Polymorphisms in Keratoconus,” Molecular Biology Reports 48, no. 11 (September 2021): 7165–7170, https://doi.org/10.1007/s11033‐021‐06708‐z. ; J. M. de Araujo Andrade, C. B. S. de Oliveira, Y. da Silva Rodrigues Meurer, et al., “Genetic Polymorphism in IL17RA Induces Susceptibility to Toxoplasma gondii Infection in Brazilian Pregnant Women,” Acta Tropica 211 (November 2020): 105594, https://doi.org/10.1016/j.actatropica.2020.105594. ; A. Raouf‐Rahmati, A.‐R. Ansar, S. A. Rezaee, et al., “Local and Systemic Gene Expression Levels of IL‐10, IL‐17 and TGF‐β in Active Ocular Toxoplasmosis in Humans,” Cytokine 146 (October 2021): 155643, https://doi.org/10.1016/j.cyto.2021.155643. ; A. Kikumura, T. Ishikawa, and K. Norose, “Kinetic Analysis of Cytokines, Chemokines, Chemokine Receptors and Adhesion Molecules in Murine Ocular Toxoplasmosis,” The British Journal of Ophthalmology 96, no. 9 (July 2012): 1259–1267, https://doi.org/10.1136/bjophthalmol‐2012‐301490. ; A. Sauer, E. Rochet, I. Lahmar, et al., “The Local Immune Response to Intraocular Toxoplasma Re‐Challenge: Less Pathology and Better Parasite Control Through Treg/Th1/Th2 Induction,” International Journal for Parasitology 43, no. 9 (August 2013): 721–728, https://doi.org/10.1016/j.ijpara.2013.04.004. ; N. N. Baqer, E. J. Saheb, and N. S. Ahmed, “Genetic Polymorphism of IL‐17A (rs2275913) in Iraqi Women With Recurrent Abortion and Its Relationship With Susceptibility to Toxoplasmosis,” Meta Gene 29 (September 2021): 100939, https://doi.org/10.1016/j.mgene.2021.100939. ; S. J. Dunstan, K. A. Rockett, N. T. N. Quyen, et al., “Variation in Human Genes Encoding Adhesion and Proinflammatory Molecules Are Associated With Severe Malaria in the Vietnamese,” Genes and Immunity 13, no. 6 (June 2012): 503–508, https://doi.org/10.1038/gene.2012.25. ; C. A. Cordeiro, P. R. Moreira, M. S. Andrade, et al., “Interleukin‐10 Gene Polymorphism (−1082G/A) Is Associated With Toxoplasmic Retinochoroiditis,” Investigative Ophthalmology & Visual Science 49, no. 5 (May 2008): 1979–1982, https://doi.org/10.1167/iovs.07‐1393. ; C. A. Cordeiro, P. R. Moreira, G. C. Costa, et al., “Interleukin‐1 Gene Polymorphisms and Toxoplasmic Retinochoroiditis,” Molecular Vision 14 (2008): 1845–1849. ; C. A. Cordeiro, P. R. Moreira, G. C. Costa, et al., “TNF‐Gene Polymorphism (−308G/A) and Toxoplasmic Retinochoroiditis,” The British Journal of Ophthalmology 92, no. 7 (June 2008): 986–988, https://doi.org/10.1136/bjo.2008.140590. ; M. C. de Albuquerque, A. L. Q. do Couto Aleixo, E. I. Benchimol, et al., “The IFN‐gamma +874T/A Gene Polymorphism Is Associated With Retinochoroiditis Toxoplasmosis Susceptibility,” Memórias do Instituto Oswaldo Cruz 104, no. 3 (May 2009): 451–455, https://doi.org/10.1590/s0074‐02762009000300009. ; W. M. R. Araujo, C. M. Ayo, M. Previato, et al., “Role of Interleukin 1β and Interleukin 10 Variants on Ocular Toxoplasmosis in Brazilian Individuals,” Frontiers in Ophthalmology 29 (June 2023): 3, https://doi.org/10.3389/fopht.2023.1183167. ; C. A. Naranjo‐Galvis, A. de‐la‐Torre, L. E. Mantilla‐Muriel, et al., “Genetic Polymorphisms in Cytokine Genes in Colombian Patients With Ocular Toxoplasmosis,” Infection and Immunity 86, no. 4 (April 2018): e00597‐17, https://doi.org/10.1128/iai.00597‐17. ; S. Yao, C.‐C. Hong, E. A. Ruiz‐Narváez, et al., “Genetic Ancestry and Population Differences in Levels of Inflammatory Cytokines in Women: Role for Evolutionary Selection and Environmental Factors,” PLoS Genetics 14, no. 6 (June 2018): e1007368, https://doi.org/10.1371/journal.pgen.1007368. ; L. E. Mantilla‐Muriel, A. Hernández‐de‐Los‐Ríos, M. Rincón, et al., “Serotyping, Host Genes and Cytokines Response in Human Ocular Toxoplasmosis,” Microbial Pathogenesis 148 (November 2020): 104465, https://doi.org/10.1016/j.micpath.2020.104465. ; C. N. Nagineni, B. Detrick, and J. J. Hooks, “Toxoplasma gondii Infection Induces Gene Expression and Secretion of Interleukin 1 (IL‐1), IL‐6, Granulocyte‐Macrophage Colony‐Stimulating Factor, and Intercellular Adhesion Molecule 1 by Human Retinal Pigment Epithelial Cells,” Infection and Immunity 68, no. 1 (January 2000): 407–410, https://doi.org/10.1128/IAI.68.1.407‐410.2000. ; C. S. Meira, V. L. Pereira‐Chioccola, J. E. Vidal, et al., “Cerebral and Ocular Toxoplasmosis Related With IFN‐γ, TNF‐α, and IL‐10 Levels,” Frontiers in Microbiology 13, no. 5 (October 2014): 492, https://doi.org/10.3389/fmicb.2014.00492. ; A. Sauer, O. Villard, C. Creuzot‐Garcher, et al., “Intraocular Levels of Interleukin 17A (IL‐17A) and IL‐10 as Respective Determinant Markers of Toxoplasmosis and Viral Uveitis,” Clinical and Vaccine Immunology 22, no. 1 (January 2015): 72–78, https://doi.org/10.1128/CVI.00423‐14. ; A. de‐la‐Torre, A. W. Pfaff, M. E. Grigg, O. Villard, E. Candolfi, and J. E. Gomez‐Marin, “Ocular Cytokinome Is Linked to Clinical Characteristics in Ocular Toxoplasmosis,” Cytokine 68, no. 1 (July 2014): 23–31, https://doi.org/10.1016/j.cyto.2014.03.005. ; A. T. Eraghi, J. G. Garweg, and U. Pleyer, “The Role of Age in Ocular Toxoplasmosis: Clinical Signs of Immunosenescence and Inflammaging,” Frontiers in Medicine 11 (March 2024): 1311145, https://doi.org/10.3389/fmed.2024.1311145. ; J. M. Furtado, K. L. Winthrop, N. J. Butler, and J. R. Smith, “Ocular Toxoplasmosis I: Parasitology, Epidemiology and Public Health,” Clinical & Experimental Ophthalmology 41, no. 1 (July 2012): 82–94, https://doi.org/10.1111/j.1442‐9071.2012.02821.x. ; J. P. Dubey, E. G. Lago, S. M. Gennari, C. Su, and J. L. Jones, “Toxoplasmosis in Humans and Animals in Brazil: High Prevalence, High Burden of Disease, and Epidemiology,” Parasitology 139, no. 11 (July 2012): 1375–1424, https://doi.org/10.1017/s0031182012000765. ; E. A. Rosenberg and L. C. Sperazza, “The Visually Impaired Patient,” American Family Physician 77, no. 10 (May 2008): 1431–1436. ; L. C. P. Assoni, F. Nakashima, V. P. de Sousa, et al., “Seroepidemiology of Toxoplasma gondii Infection in Blood Donors in a Population From the Northwestern Region of São Paulo State, Brazil,” Transactions of the Royal Society of Tropical Medicine and Hygiene 118 (August 2023): 102–109, https://doi.org/10.1093/trstmh/trad060.
- Grant Information: 001 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; 09/2022 Conselho Nacional de Desenvolvimento Científico e Tecnológico; 2013/25650-8 Fundação de Amparo à Pesquisa do Estado de São Paulo; 2013/06580-9 Fundação de Amparo à Pesquisa do Estado de São Paulo; 2013/10050-5 Fundação de Amparo à Pesquisa do Estado de São Paulo
- Contributed Indexing: Keywords: Toxoplasma gondii; cytokine; interleukin 17; ocular toxoplasmosis; polymorphism
- Substance Nomenclature: 0 (IL17F protein, human)
- Entry Date(s): Date Created: 20240520 Date Completed: 20240520 Latest Revision: 20240520
- Update Code: 20240520
|
